Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 72 | 2024 | 2882 | 4.600 |
Why?
|
Radiotherapy, Intensity-Modulated | 20 | 2022 | 807 | 3.580 |
Why?
|
Carcinoma, Squamous Cell | 54 | 2023 | 4022 | 2.920 |
Why?
|
Oropharyngeal Neoplasms | 15 | 2023 | 491 | 1.630 |
Why?
|
Taxoids | 18 | 2013 | 667 | 1.130 |
Why?
|
Radiation Oncology | 5 | 2023 | 560 | 1.120 |
Why?
|
Paclitaxel | 21 | 2019 | 1705 | 1.060 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2019 | 101 | 0.940 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2021 | 11609 | 0.930 |
Why?
|
Carcinoma, Adenoid Cystic | 6 | 2021 | 258 | 0.850 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 11 | 2022 | 1678 | 0.800 |
Why?
|
Papillomavirus Infections | 10 | 2023 | 1600 | 0.760 |
Why?
|
Radiotherapy Dosage | 23 | 2022 | 2915 | 0.710 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9258 | 0.690 |
Why?
|
Radiation-Sensitizing Agents | 6 | 2003 | 345 | 0.670 |
Why?
|
Malpractice | 2 | 2023 | 553 | 0.610 |
Why?
|
Radiation Injuries | 3 | 2019 | 1186 | 0.600 |
Why?
|
Neoplasms, Squamous Cell | 2 | 2009 | 96 | 0.590 |
Why?
|
Combined Modality Therapy | 34 | 2023 | 8556 | 0.570 |
Why?
|
Laryngeal Neoplasms | 6 | 2022 | 515 | 0.560 |
Why?
|
Carboplatin | 11 | 2019 | 790 | 0.540 |
Why?
|
Salivary Gland Neoplasms | 3 | 2020 | 302 | 0.490 |
Why?
|
Fluorouracil | 20 | 2019 | 1604 | 0.490 |
Why?
|
Esophageal Stenosis | 4 | 2013 | 195 | 0.490 |
Why?
|
Cisplatin | 21 | 2020 | 1649 | 0.480 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 2006 | 614 | 0.440 |
Why?
|
Mouth Neoplasms | 3 | 2020 | 593 | 0.410 |
Why?
|
Papillomaviridae | 8 | 2020 | 1105 | 0.410 |
Why?
|
Hypopharyngeal Neoplasms | 3 | 2011 | 49 | 0.390 |
Why?
|
Carcinoma, Merkel Cell | 3 | 2022 | 321 | 0.390 |
Why?
|
Radiotherapy, Adjuvant | 14 | 2020 | 1778 | 0.380 |
Why?
|
Skin Neoplasms | 6 | 2023 | 5785 | 0.370 |
Why?
|
Disease-Free Survival | 14 | 2021 | 6795 | 0.360 |
Why?
|
Human papillomavirus 16 | 1 | 2012 | 266 | 0.350 |
Why?
|
Osteoradionecrosis | 2 | 2021 | 51 | 0.330 |
Why?
|
Neoplasm Staging | 21 | 2024 | 11109 | 0.330 |
Why?
|
Deglutition Disorders | 6 | 2016 | 620 | 0.320 |
Why?
|
Xerostomia | 5 | 2018 | 94 | 0.310 |
Why?
|
Middle Aged | 73 | 2024 | 218133 | 0.290 |
Why?
|
Immobilization | 1 | 2008 | 230 | 0.290 |
Why?
|
Cancer Care Facilities | 3 | 2019 | 424 | 0.280 |
Why?
|
Rhabdomyosarcoma | 1 | 2010 | 359 | 0.280 |
Why?
|
Neoplasms, Second Primary | 2 | 2014 | 1059 | 0.270 |
Why?
|
Survival Analysis | 12 | 2020 | 10180 | 0.270 |
Why?
|
Neck Dissection | 6 | 2011 | 203 | 0.270 |
Why?
|
Vinblastine | 3 | 2014 | 487 | 0.260 |
Why?
|
Aged | 64 | 2024 | 167433 | 0.260 |
Why?
|
Radiation Tolerance | 3 | 2012 | 479 | 0.260 |
Why?
|
Humans | 125 | 2024 | 755800 | 0.250 |
Why?
|
Radiotherapy, Conformal | 5 | 2008 | 550 | 0.240 |
Why?
|
Male | 74 | 2024 | 356684 | 0.240 |
Why?
|
Retrospective Studies | 33 | 2024 | 79735 | 0.230 |
Why?
|
Cyclins | 2 | 1996 | 594 | 0.220 |
Why?
|
Female | 72 | 2024 | 388048 | 0.220 |
Why?
|
Polyglutamic Acid | 1 | 2003 | 44 | 0.220 |
Why?
|
Lymphoma | 2 | 2010 | 1890 | 0.210 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2016 | 2900 | 0.190 |
Why?
|
Neuroblastoma | 1 | 2010 | 1241 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 8 | 2008 | 875 | 0.190 |
Why?
|
Bromodeoxyuridine | 2 | 1992 | 310 | 0.190 |
Why?
|
Antineoplastic Agents | 9 | 2020 | 13579 | 0.190 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2017 | 288 | 0.190 |
Why?
|
Lymph Nodes | 3 | 2015 | 3483 | 0.190 |
Why?
|
Neoadjuvant Therapy | 4 | 2021 | 2808 | 0.190 |
Why?
|
Alkaloids | 2 | 1992 | 194 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6522 | 0.180 |
Why?
|
Aged, 80 and over | 26 | 2024 | 58563 | 0.180 |
Why?
|
Leucovorin | 8 | 2004 | 614 | 0.180 |
Why?
|
Dilatation | 2 | 2013 | 303 | 0.180 |
Why?
|
Adult | 48 | 2024 | 218056 | 0.170 |
Why?
|
Acupuncture Therapy | 2 | 2016 | 474 | 0.170 |
Why?
|
Stomatitis | 3 | 2009 | 270 | 0.170 |
Why?
|
Erythrocyte Membrane | 2 | 1993 | 439 | 0.170 |
Why?
|
Organs at Risk | 2 | 2022 | 362 | 0.160 |
Why?
|
Radiometry | 4 | 2008 | 817 | 0.160 |
Why?
|
Carcinoma | 2 | 2023 | 2345 | 0.160 |
Why?
|
Sarcopenia | 1 | 2023 | 369 | 0.150 |
Why?
|
Relative Biological Effectiveness | 3 | 2008 | 321 | 0.150 |
Why?
|
Positron-Emission Tomography | 4 | 2009 | 6451 | 0.140 |
Why?
|
Tumor Burden | 4 | 2021 | 1888 | 0.140 |
Why?
|
Treatment Outcome | 23 | 2021 | 64560 | 0.140 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 73 | 0.140 |
Why?
|
Skin Physiological Phenomena | 2 | 2008 | 188 | 0.140 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.140 |
Why?
|
Maximum Tolerated Dose | 4 | 2019 | 873 | 0.130 |
Why?
|
Nocodazole | 1 | 1995 | 95 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 166 | 0.130 |
Why?
|
Melanoma | 1 | 2014 | 5657 | 0.130 |
Why?
|
Mucous Membrane | 1 | 2019 | 656 | 0.130 |
Why?
|
Mucositis | 2 | 2019 | 106 | 0.120 |
Why?
|
Radiation Dosage | 4 | 2022 | 1974 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2013 | 3517 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 74 | 0.120 |
Why?
|
Abducens Nerve | 1 | 1993 | 28 | 0.120 |
Why?
|
Parotid Gland | 2 | 2022 | 175 | 0.110 |
Why?
|
Monte Carlo Method | 3 | 2009 | 1268 | 0.110 |
Why?
|
Trochlear Nerve | 1 | 1993 | 25 | 0.110 |
Why?
|
Skin | 1 | 2007 | 4445 | 0.110 |
Why?
|
Radiotherapy | 3 | 2010 | 1508 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12502 | 0.110 |
Why?
|
Oculomotor Nerve | 1 | 1993 | 72 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2019 | 856 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2009 | 10811 | 0.110 |
Why?
|
Cavernous Sinus | 1 | 1993 | 122 | 0.100 |
Why?
|
Carcinoma, Ductal | 1 | 2013 | 97 | 0.100 |
Why?
|
SEER Program | 4 | 2020 | 1524 | 0.100 |
Why?
|
Saliva | 1 | 2017 | 815 | 0.100 |
Why?
|
Benchmarking | 1 | 2018 | 1039 | 0.100 |
Why?
|
Consensus | 2 | 2022 | 3057 | 0.100 |
Why?
|
Trigeminal Nerve | 1 | 1993 | 243 | 0.100 |
Why?
|
Treatment Failure | 3 | 2012 | 2637 | 0.100 |
Why?
|
Tumor Cells, Cultured | 4 | 1992 | 6140 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 895 | 0.100 |
Why?
|
Survival Rate | 7 | 2017 | 12784 | 0.100 |
Why?
|
Laryngectomy | 3 | 2013 | 244 | 0.100 |
Why?
|
Esophagoscopy | 1 | 2013 | 392 | 0.100 |
Why?
|
Remission Induction | 4 | 2009 | 2387 | 0.090 |
Why?
|
Astrocytoma | 2 | 1992 | 778 | 0.090 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39189 | 0.090 |
Why?
|
Prognosis | 10 | 2024 | 29430 | 0.090 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 89 | 0.090 |
Why?
|
Deglutition | 1 | 2011 | 202 | 0.090 |
Why?
|
Optic Nerve | 1 | 1993 | 566 | 0.090 |
Why?
|
Amifostine | 1 | 2009 | 40 | 0.090 |
Why?
|
Microtubules | 1 | 1995 | 1078 | 0.090 |
Why?
|
Esophagitis | 1 | 2010 | 164 | 0.080 |
Why?
|
3T3 Cells | 3 | 1996 | 1084 | 0.080 |
Why?
|
Albumins | 1 | 2012 | 566 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2009 | 2001 | 0.080 |
Why?
|
Retreatment | 1 | 2010 | 599 | 0.080 |
Why?
|
Dermatitis | 1 | 2010 | 200 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1362 | 0.080 |
Why?
|
Dental Restoration, Permanent | 1 | 2009 | 130 | 0.080 |
Why?
|
Veterans | 1 | 2022 | 2614 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1587 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 677 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1703 | 0.080 |
Why?
|
Boston | 2 | 2011 | 9259 | 0.080 |
Why?
|
Lymphatic Metastasis | 4 | 2015 | 2935 | 0.080 |
Why?
|
Transistors, Electronic | 1 | 2007 | 21 | 0.070 |
Why?
|
Technology, Radiologic | 1 | 2007 | 161 | 0.070 |
Why?
|
DNA Damage | 2 | 1996 | 2413 | 0.070 |
Why?
|
Markov Chains | 3 | 2018 | 975 | 0.070 |
Why?
|
Dacarbazine | 2 | 2014 | 560 | 0.070 |
Why?
|
Salvage Therapy | 2 | 2021 | 1265 | 0.070 |
Why?
|
Tongue Neoplasms | 2 | 2006 | 183 | 0.070 |
Why?
|
Risk Assessment | 5 | 2019 | 23960 | 0.070 |
Why?
|
Erythrocytes | 2 | 1993 | 2405 | 0.070 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 27 | 0.070 |
Why?
|
Models, Biological | 3 | 2008 | 9460 | 0.070 |
Why?
|
Antibodies, Monoclonal | 4 | 2012 | 9110 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 4875 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2014 | 1376 | 0.070 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3120 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2789 | 0.060 |
Why?
|
Models, Economic | 1 | 2009 | 718 | 0.060 |
Why?
|
Submandibular Gland | 1 | 2005 | 87 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 5 | 2023 | 20415 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8014 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1996 | 359 | 0.060 |
Why?
|
DNA | 2 | 2022 | 7225 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Young Adult | 8 | 2020 | 58041 | 0.060 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2006 | 240 | 0.060 |
Why?
|
Pharynx | 1 | 2007 | 430 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5752 | 0.060 |
Why?
|
Base Sequence | 4 | 2016 | 12444 | 0.060 |
Why?
|
Quality-Adjusted Life Years | 3 | 2018 | 1716 | 0.060 |
Why?
|
Radiosurgery | 1 | 1993 | 1334 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2887 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3825 | 0.060 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 14640 | 0.050 |
Why?
|
Larynx | 1 | 2008 | 493 | 0.050 |
Why?
|
Survivors | 1 | 2014 | 2335 | 0.050 |
Why?
|
Insurance, Liability | 1 | 2023 | 101 | 0.050 |
Why?
|
Gastroscopy | 1 | 2004 | 208 | 0.050 |
Why?
|
Radiopharmaceuticals | 3 | 2009 | 2672 | 0.050 |
Why?
|
Gastrostomy | 2 | 2018 | 317 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 2 | 1992 | 2003 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2008 | 902 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 1995 | 7577 | 0.050 |
Why?
|
Neoplasms | 2 | 2018 | 21895 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5790 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2003 | 628 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3506 | 0.050 |
Why?
|
Metalloporphyrins | 1 | 2001 | 40 | 0.050 |
Why?
|
Automation | 1 | 2023 | 584 | 0.050 |
Why?
|
Prescriptions | 1 | 2023 | 388 | 0.050 |
Why?
|
Observer Variation | 1 | 2007 | 2594 | 0.050 |
Why?
|
Quality of Life | 5 | 2022 | 13204 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10684 | 0.050 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 2326 | 0.040 |
Why?
|
Cytokines | 2 | 2016 | 7264 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2684 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2007 | 2501 | 0.040 |
Why?
|
Scattering, Radiation | 2 | 1993 | 490 | 0.040 |
Why?
|
Laryngoscopy | 1 | 2004 | 706 | 0.040 |
Why?
|
Cost of Illness | 1 | 2008 | 1926 | 0.040 |
Why?
|
Elasticity | 2 | 1993 | 653 | 0.040 |
Why?
|
Dysgeusia | 1 | 2018 | 15 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2001 | 392 | 0.040 |
Why?
|
Cohort Studies | 6 | 2021 | 41122 | 0.040 |
Why?
|
Prospective Studies | 8 | 2020 | 54015 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 152 | 0.040 |
Why?
|
Molecular Sequence Data | 3 | 1996 | 17610 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2226 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2018 | 5499 | 0.040 |
Why?
|
Artifacts | 1 | 2006 | 1896 | 0.040 |
Why?
|
Brachytherapy | 1 | 2005 | 1241 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4887 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11314 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2012 | 5187 | 0.040 |
Why?
|
Neck | 2 | 2016 | 727 | 0.040 |
Why?
|
Mandible | 1 | 2021 | 741 | 0.030 |
Why?
|
Jaw | 1 | 2017 | 93 | 0.030 |
Why?
|
Photosensitizing Agents | 1 | 2001 | 608 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2489 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2001 | 665 | 0.030 |
Why?
|
Nausea | 1 | 1999 | 673 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 906 | 0.030 |
Why?
|
Medical Errors | 1 | 2023 | 1253 | 0.030 |
Why?
|
Incidence | 4 | 2020 | 21248 | 0.030 |
Why?
|
Disease Progression | 2 | 2009 | 13433 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2024 | 6066 | 0.030 |
Why?
|
Light | 2 | 1993 | 1338 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12160 | 0.030 |
Why?
|
Procarbazine | 1 | 2014 | 172 | 0.030 |
Why?
|
Mechlorethamine | 1 | 2014 | 130 | 0.030 |
Why?
|
Erythrocyte Aging | 1 | 1993 | 53 | 0.030 |
Why?
|
Computer Simulation | 4 | 2009 | 6191 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1823 | 0.030 |
Why?
|
Databases, Factual | 2 | 2023 | 7950 | 0.030 |
Why?
|
Algorithms | 2 | 2023 | 13957 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 452 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1995 | 775 | 0.030 |
Why?
|
Morpholines | 1 | 2017 | 587 | 0.030 |
Why?
|
Electrophoresis | 1 | 1993 | 233 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 565 | 0.030 |
Why?
|
Dactinomycin | 1 | 1993 | 303 | 0.030 |
Why?
|
Cranial Nerve Diseases | 1 | 1993 | 112 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6313 | 0.030 |
Why?
|
Bleomycin | 1 | 2014 | 497 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 498 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 508 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 696 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20893 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1337 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2022 | 1818 | 0.020 |
Why?
|
Child | 4 | 2016 | 79453 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2006 | 2479 | 0.020 |
Why?
|
Antibody Formation | 1 | 2016 | 1381 | 0.020 |
Why?
|
Cell Survival | 2 | 1992 | 5783 | 0.020 |
Why?
|
Vincristine | 1 | 2014 | 1030 | 0.020 |
Why?
|
Interphase | 1 | 1992 | 229 | 0.020 |
Why?
|
Adolescent | 7 | 2016 | 87249 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1442 | 0.020 |
Why?
|
Pilot Projects | 2 | 2016 | 8490 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2017 | 1391 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1992 | 642 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1543 | 0.020 |
Why?
|
Oligonucleotides | 1 | 1993 | 589 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2012 | 411 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 1993 | 730 | 0.020 |
Why?
|
Camptothecin | 1 | 1993 | 581 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2014 | 857 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2019 | 1580 | 0.020 |
Why?
|
Communication | 1 | 2023 | 3815 | 0.020 |
Why?
|
Time Factors | 4 | 2011 | 39975 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18369 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1564 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2179 | 0.020 |
Why?
|
Patient Selection | 2 | 2012 | 4256 | 0.020 |
Why?
|
Dental Amalgam | 1 | 2009 | 66 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2012 | 5180 | 0.020 |
Why?
|
Cytoskeleton | 1 | 1993 | 1168 | 0.020 |
Why?
|
Microscopy | 1 | 1993 | 882 | 0.020 |
Why?
|
Dental Materials | 1 | 2009 | 111 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 888 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2016 | 9565 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2011 | 6236 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8446 | 0.020 |
Why?
|
Child, Preschool | 3 | 2016 | 41911 | 0.020 |
Why?
|
Cell Cycle | 1 | 1995 | 2932 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2196 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1864 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2496 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2017 | 2176 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15214 | 0.020 |
Why?
|
Mitosis | 1 | 1992 | 1199 | 0.020 |
Why?
|
Decision Making | 1 | 2000 | 3898 | 0.020 |
Why?
|
Brain Neoplasms | 2 | 2001 | 8917 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 1995 | 11897 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2017 | 3728 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1438 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11027 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 2009 | 721 | 0.020 |
Why?
|
Iridium Radioisotopes | 1 | 2005 | 26 | 0.020 |
Why?
|
Online Systems | 1 | 2006 | 180 | 0.020 |
Why?
|
Pituitary Neoplasms | 1 | 1993 | 1309 | 0.020 |
Why?
|
Antibodies | 1 | 1993 | 2415 | 0.020 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2005 | 91 | 0.020 |
Why?
|
Cell Division | 1 | 1992 | 4448 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2304 | 0.010 |
Why?
|
Reproducibility of Results | 3 | 2008 | 19996 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4515 | 0.010 |
Why?
|
Cholesterol | 1 | 1993 | 2921 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 848 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1995 | 5793 | 0.010 |
Why?
|
Mice | 3 | 1996 | 80753 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3606 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 136 | 0.010 |
Why?
|
Risk Factors | 3 | 2020 | 73885 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3607 | 0.010 |
Why?
|
Organ Specificity | 1 | 2008 | 1954 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 462 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2011 | 15753 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1539 | 0.010 |
Why?
|
Physical Examination | 1 | 2009 | 1240 | 0.010 |
Why?
|
United States | 2 | 2022 | 71902 | 0.010 |
Why?
|
Cytoplasm | 1 | 1987 | 1523 | 0.010 |
Why?
|
Feedback | 1 | 2006 | 786 | 0.010 |
Why?
|
Motion | 1 | 2006 | 784 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13316 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8439 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8405 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 2009 | 1271 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25704 | 0.010 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2003 | 325 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 694 | 0.010 |
Why?
|
Recovery of Function | 1 | 2011 | 2933 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1106 | 0.010 |
Why?
|
Protein Binding | 1 | 1993 | 9307 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1995 | 12756 | 0.010 |
Why?
|
Calcium | 1 | 1993 | 5707 | 0.010 |
Why?
|
Drug Synergism | 1 | 2004 | 1748 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2003 | 622 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10494 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9374 | 0.010 |
Why?
|
France | 1 | 2001 | 507 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12928 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2004 | 999 | 0.010 |
Why?
|
Animals | 3 | 1996 | 167168 | 0.010 |
Why?
|
Equipment Design | 1 | 2007 | 3524 | 0.010 |
Why?
|
Thyrotropin | 1 | 2001 | 830 | 0.010 |
Why?
|
Fibrosis | 1 | 2005 | 2025 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12347 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4679 | 0.010 |
Why?
|
Palliative Care | 1 | 2013 | 3597 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 1999 | 429 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2001 | 2286 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1993 | 7827 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26046 | 0.010 |
Why?
|
Research Design | 1 | 2012 | 6144 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10254 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2001 | 1302 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2008 | 4045 | 0.010 |
Why?
|
Infant | 1 | 2016 | 35883 | 0.010 |
Why?
|
ROC Curve | 1 | 2001 | 3558 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2008 | 3723 | 0.010 |
Why?
|
HIV Infections | 1 | 2019 | 17054 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5066 | 0.010 |
Why?
|
Odds Ratio | 1 | 2001 | 9721 | 0.010 |
Why?
|
Diet | 1 | 2006 | 7967 | 0.000 |
Why?
|
Inflammation | 1 | 2005 | 10720 | 0.000 |
Why?
|